Brief overview of the end points of thrombolytic therapy.
In addition to mortality, several measurable end points of thrombolytic therapy have been studied. These include coronary arterial patency, left ventricular function, reocclusion, reinfarction, and bleeding complications. Current wisdom dictates that recanalization of occluded arteries in the early phases of acute myocardial infarction should be attempted to preserve viable cardiac muscle, with the ultimate goal of decreasing mortality. Unfortunately, the number of patients eligible for thrombolytic therapy far exceeds the number receiving it, despite the clear benefits that have been demonstrated.
Conti
C R
CR
Department of Medicine, University of Florida College of Medicine, Gainesville 32610.
D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D015912:Thrombolytic Therapy
D005343:Fibrinolytic Agents